Dynavax Technologies Corporation (DVAX) Q2 2025 Earnings Call Transcript

Dynavax Technologies reported a record Q2 2025, with HEPLISAV-B net product revenue reaching $92 million, a 31% year-over-year increase, contributing to $95 million in total revenue. The company raised its full-year 2025 HEPLISAV-B revenue guidance to $315-$325 million, driven by its market-leading 45% share in the U.S. adult hepatitis B vaccine market and the ongoing shift towards retail channels, targeting over 60% market share in a market projected to exceed $900 million by 2030. Dynavax also completed its $200 million share repurchase program and anticipates top-line Phase I/II results for its novel shingles vaccine program in the coming weeks, alongside continued advancement of its pandemic influenza and DoD-funded plague vaccine programs.

Analysis

Dynavax Technologies delivered a strong Q2 2025, underscored by record net product revenue for HEPLISAV-B of $92 million, a 31% year-over-year increase. This performance prompted an upward revision of full-year 2025 revenue guidance to a range of $315 million to $325 million. The growth is fueled by expanding U.S. market share, which rose to 45% from 42% in the prior-year quarter, and a significant structural shift in the hepatitis B market toward the retail channel, where Dynavax holds a dominant 57% trailing 12-month share. A recent Medicare policy change allowing reimbursement for HEPLISAV-B in retail settings provides a new tailwind, enhancing access to the 25% of retail doses administered to patients over 65. The company reaffirmed its long-term outlook of capturing at least 60% of a U.S. market projected to exceed $900 million by 2030. Financially, the company reported improved profitability with adjusted EBITDA of $37 million and completed a $200 million share repurchase program. The clinical pipeline is advancing, with the most significant near-term catalyst being the imminent top-line Phase I/II data for its novel shingles vaccine program, which aims to challenge a multi-billion dollar market. Other pipeline assets, including a pandemic influenza program and a DoD-funded plague vaccine, continue to progress, leveraging the core CpG 1018 adjuvant technology.

Key Decisions for Investors

• The strong momentum and raised guidance for HEPLISAV-B, bolstered by the structural shift to retail and favorable Medicare policy changes, support a positive outlook on the core commercial asset; investors should continue to monitor market share gains against the company's 60% long-term target.
• The upcoming top-line data from the Phase I/II shingles vaccine trial is the most significant near-term catalyst and could substantially re-rate the stock if results demonstrate a competitive immunogenicity and safety profile.
• Investors should note that $6.6 million of the Q2 revenue was from non-recurring items, and therefore focus on underlying dose volume growth in the second half of the year to validate the sustained growth trajectory.
• With the $200 million share repurchase now complete, future value creation will hinge on disciplined capital allocation between advancing the maturing pipeline and opportunistic business development, which should be closely monitored.